Cosmos Health Inc. has entered the global beauty and personal care market, launching a premium, Korean-developed collagen-based skincare line in the United States. The move targets the $163 billion global skincare market, which is projected to reach approximately $203 billion by 2033, according to Grand View Research. This strategic expansion aims to diversify the company's portfolio into higher-margin, high-growth categories.

Sales of the new brand have been live for over a month in the U.S., utilizing a direct-to-consumer model designed for global scale. Cosmos Health plans to roll out a series of products, pursuing a multi-brand strategy to deepen its presence in the skincare sector. The company stated that premium skincare is among the fastest-growing segments, driven by rising consumer demand for science-backed formulations.

Greg Siokas, CEO of Cosmos Health, emphasized that entering the beauty market is a natural extension of the company's strategy. He highlighted that the direct-to-consumer model and planned multi-brand portfolio are expected to contribute significantly to future growth. The launch marks a key step in the company's diversification toward more lucrative end markets.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. The company owns proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, and bio-bebe®. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, and cosmetics within the European Union.

The company distributes pharmaceuticals and parapharmaceuticals to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Cosmos Health has also established R&D partnerships targeting major health disorders and entered the telehealth space via the acquisition of ZipDoctor, Inc. Its global distribution platform includes offices and distribution centers in Greece and the UK.

Cosmos Health Inc. has projected over $22.7 million in annualized U.S. revenue and approximately $17.0 million in implied gross profit from its 18 Series nutraceutical platform, operating at ~75% gross margins. The company, listed on NASDAQ under the symbol COSM, disclosed these targets for four of its five launched products, highlighting early demand and commercial traction in the U.S. market.

The 18 Series is a science-driven platform built on proprietary ingredients, published clinical research, and exact clinical dosing. Since its U.S. launch, Cosmos Health has introduced five products: Noor18™, Liv18™, Cur18™, Fort18™, and Oliv18™. The company expects the platform to become a significant pillar of long-term revenue and a meaningful contributor to profitability.

Financial Projections

The revenue and gross profit figures are based on the company's ~75% gross-margin guidance applied to disclosed revenue projections for four products. The total excludes Oliv18™, which has been launched but does not yet have a disclosed revenue projection.

¹ Gross profit is calculated by applying the Company's approximately 75% gross-margin guidance to its disclosed revenue projections. Total excludes Oliv18™, which is launched but has no disclosed revenue projection.

Strategic Outlook

Cosmos Health is targeting a portfolio of 18 science-based products spanning key health categories. The platform remains at an early stage, and the company expects to provide further updates as additional products are launched and commercial data develops.